S 1096

The Preserve Access to Affordable Generics and Biosimilars Act aims to prevent pharmaceutical companies from making deals that delay the availability of lower-cost generic drugs and biosimilars. Specifically, it prohibits agreements where a brand-name drug company compensates a generic or biosimilar competitor to limit competition, such as by restricting research, development, or sales. The Federal Trade Commission (FTC) will enforce these rules, and violators could forfeit marketing exclusivity periods. The bill also requires companies to certify agreements to ensure transparency and prevent hidden payments.